drugset / Trial / NCT00005072
Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer
Phase 1/2
Terminated
25 enrolled
Vical
Jonsson Comprehensive Cancer Center · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Inserting the gene for interleukin-2 into a person's prostate cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of Leuvectin in treating patients who have locally recurrent prostate cancer after receiving treatment with radiation therapy.
Timeline
- Start
- 2000-11
- Primary completion
- 2003-04
- Completion
- 2003-04
Outcome
Outcome not reported
Stopped: “Development in prostate cancer indication halted”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuvectin | Other / unclassified | 1000 ug | Other |